- Home
- CTRM vs QNRX Comparison
CTRM vs QNRX Comparison
Compare CTRM & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTRM | QNRX |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 17.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CTRM | QNRX |
|---|---|---|
| Price | $1.97 | $21.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 37.7K | ★ 1.0M |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,859,415.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.84 | $5.01 |
| 52 Week High | $3.64 | $48.30 |
Technical Indicators
Market Signals| Indicator | CTRM | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 69.30 |
| Support Level | $1.85 | $16.50 |
| Resistance Level | $1.99 | $23.50 |
| Average True Range (ATR) | 0.07 | 2.85 |
| MACD | 0.01 | 0.78 |
| Stochastic Oscillator | 48.83 | 88.09 |
Price Performance
Historical ComparisonAbout CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.